Tissue engineered skin for diabetic foot ulcers: a meta-analysis

Area of Science:

• Regenerative Medicine
• Wound Healing
• Diabetic Complications

Background:

• Diabetic foot ulcers (DFUs) are a major cause of morbidity and limb loss.
• Conventional treatments for DFUs have limited efficacy, necessitating advanced therapeutic options.

Purpose of the Study:

• To evaluate the effectiveness of tissue engineered skin (TES) in managing diabetic foot ulcers.
• To compare TES interventions against conventional treatments using a meta-analysis approach.

Main Methods:

• A systematic search of PubMed, EMBASE, and ISI Web of Science identified randomized controlled trials.
• Meta-analysis was performed using STATA 11 software, analyzing pooled odds ratios (OR) and 95% confidence intervals (CI).
• Funnel plots were used to assess publication bias.

Main Results:

• Eight studies involving 1060 patients were included.
• Tissue engineered skin showed a pooled OR of 1.76 (95% CI: 1.35-2.30) for improved wound closure.
• Subgroup analyses indicated effectiveness for Derma graft (OR 1.91), Graft skin (OR 2.05), and Hyalo graft 3D (OR 1.57).

Conclusions:

• Tissue engineered skin is a more effective treatment for improving wound closure in diabetic foot ulcers than conventional methods.
• TES offers a promising therapeutic strategy for the management of DFUs.